non-small cell lung cancer

#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
Flag link:
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
ASCO: Death in Turning Point NSCLC trial overshadows 82% ORR
Fierce Biotech
ASCO 2019
clinical trials
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
Flag link:
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Flag link:
Turning Point sinks on ASCO update for repotrectinib
Turning Point sinks on ASCO update for repotrectinib
BioCentury
ASCO 2019
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
Flag link:
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Flag link:
FDA expands Keytruda approval for first-line NSCLC treatment
FDA expands Keytruda approval for first-line NSCLC treatment
Pharmaforum
Merck
Keytruda
FDA
non-small cell lung cancer
Flag link:
Liquid biopsy is as effective as tissue biopsy in lung cancer, study finds
Liquid biopsy is as effective as tissue biopsy in lung cancer, study finds
BioPharma Dive
Guardant Health
liquid biopsy
non-small cell lung cancer
Guardant360
Flag link:
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
Flag link:
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
Xconomy
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
Flag link:
AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC
AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC
Fierce Biotech
AstraZeneca
clinical trials
tremelimumab
non-small cell lung cancer
Flag link:
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
Fierce Pharma
China MediTech
Elunate
Eli Lilly
China
non-small cell lung cancer
Flag link:
Investors ding Tesaro despite responses for combo in NSCLC
Investors ding Tesaro despite responses for combo in NSCLC
BioCentury
Tesaro
non-small cell lung cancer
clinical trials
TSR-042
Flag link:
FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC
FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC
BioCentury
Bristol-Myers Squibb
Opdivo
FDA
EMA
Yervoy
non-small cell lung cancer
Flag link:
Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Pharmaceutical Business Review
Daiichi Sankyo
non-small cell lung cancer
DS-1205
Flag link:
TP Therapeutics Secures $80 Million Mezzanine Financing
TP Therapeutics Secures $80 Million Mezzanine Financing
CP Wire
TP Therapeutics
non-small cell lung cancer
repotrectinib
Flag link:
Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Endpoints
Merrimack Pharmaceuticals
MM-121
non-small cell lung cancer
Flag link:
TP Therapeutics Secures $80 Million Mezzanine Financing
TP Therapeutics
non-small cell lung cancer
repotrectinib
Flag link:
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
CP Wire
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Flag link:
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Flag link:
Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy
Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy
Endpoints
R&D
Pfizer
Ian Read
dacomitinib
FDA
non-small cell lung cancer
Flag link:

Pages